Filtered By:
Procedure: Liver Transplant
This page shows you your search results in order of date.
Order by Relevance | Date
Total 111 results found since Jan 2013.
Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines
CONCLUSIONS: Our results showed for the first time that silencing TOLLIP in hepatocellular carcinoma cells may help sensitize these cells to doxorubicin and increase the efficacy of chemotherapeutic regimens where doxorubicin is used.PMID:37644370 | DOI:10.1007/s11033-023-08737-2
Source: Mol Biol Cell - August 29, 2023 Category: Molecular Biology Authors: Ayse Banu Demir Elif Baris Umay Bengi Kaner Hani Alotaibi Nese Atabey Ahmet Koc Source Type: research
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
ConclusionsThe consistency of patisiran PK and PD between patients with and without LT suggests that neither LT nor concomitantly administered immunosuppressants influence hepatic uptake or RNAi activity of patisiran. The patisiran dosing regimen of 0.3 mg/kg q3w is appropriate for hATTR amyloidosis patients with or without LT.Clinical Trial Registration NoNCT03862807.
Source: Clinical Pharmacokinetics - August 28, 2023 Category: Drugs & Pharmacology Source Type: research
GSE178987 An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis
Contributors : Batuhan Yenilmez ; Lawrence Lifshitz ; Michael Czech ; Anastasia KhvorovaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNonalcoholic steatohepatitis (NASH) is a severe liver disorder characterized by triglyceride accumulation, severe inflammation, and fibrosis. With the recent increase in prevalence, NASH is now the leading cause of liver transplantation, with no approved therapeutics available. Despite years of research, the exact molecular mechanism of NASH progression is not well understood, but fat accumulation is believed to be the primary driver of the disease. T...
Source: GEO: Gene Expression Omnibus - December 31, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Petits ARN interf érents : applications potentielles pour les néphrologues Small interfering RNA: potential applications for nephrologists
Nephrol Ther. 2022 Dec;18(6S1):6S1-6S6. doi: 10.1016/S1769-7255(22)00646-0.ABSTRACTSmall interfering RNA (siRNAs) are double-stranded RNAs of around 20 base pairs in length that trigger RNAi machinery, which promotes degradation of a target mRNA avoiding protein translation. SiRNAs are liver-targeted, using tris N-acetylgalactosamine (GalNAc) as the targeting ligand. This discovery received the Nobel Prize for medicine and physiology in 2006 and lead to substantial therapeutic advances. Application field and development of these siRNA has been very fast. Indeed, patisiran has been released in 2018 for hereditary transthyre...
Source: Nephrologie and Therapeutique - December 30, 2022 Category: Urology & Nephrology Authors: Sandrine Lemoine Marie Courbebaisse Source Type: research
